Last Updated: July 26, 2026

Details for Patent: 11,186,547


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,186,547 protect, and when does it expire?

Patent 11,186,547 protects LENVIMA and is included in one NDA.

Protection for LENVIMA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-two patent family members in twenty-six countries.

Summary for Patent: 11,186,547
Title:High-purity quinoline derivative and method for manufacturing same
Abstract:Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.
Inventor(s):Taiju Nakamura, Taichi Abe, Yusuke Miyashita, Hirofumi Kuroda, Yusuke Ayata, Atsushi Akao
Assignee: Eisai R&D Management Co Ltd
Application Number:US17/022,675
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,186,547
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 11,186,547

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-001 Feb 13, 2015 RX Yes No 11,186,547*PED ⤷  Start Trial Y ⤷  Start Trial
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-002 Feb 13, 2015 RX Yes Yes 11,186,547*PED ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 11,186,547

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2014-174062Aug 28, 2014
Japan2015-034729Feb 25, 2015

International Family Members for US Patent 11,186,547

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 101695 ⤷  Start Trial
Australia 2015309862 ⤷  Start Trial
Brazil 112017002827 ⤷  Start Trial
Canada 2957005 ⤷  Start Trial
China 106660964 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.